EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudie

Comparison of Tenecteplase Versus Alteplase for the Treatment of Pulmonary Embolism and Cardiac Arrest with Suspected Pulmonary Embolism

Jessica M Daniell iD, Jack Mccormick, Iram Nasreen, Todd M Conner iD, Ginger Rouse, Diana Gritsenko, Akhil Khosla iD

Journal of Intensive Care Medicine · 2025

DOI: 10.1177/08850666241268539 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Intensive Care Medicine, 2025. Verfasst von Jessica M Daniell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Yale New Haven Hospital, New Haven, CT, USA. Hauptthemen laut MEDLINE: Pulmonary Embolism, Tenecteplase, Tissue Plasminogen Activator, Fibrinolytic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-risk pulmonary embolism (PE) is a life-threatening disease state with current guidelines recommending reperfusion therapy with systemic thrombolytics in addition to anticoagulation. This was a prospective observational cohort study with a historical control group comparing tenecteplase to alteplase for the treatment of PE or cardiac arrest with suspected PE. The primary outcome was the incidence of institutional protocol deviations defined as incorrect thrombolytic dose administered or the incorrect product compounded. Secondary outcomes included any bleeding event, major bleeding event, all-cause mortality, and for patients with a cardiac arrest, successful return of spontaneous circulation (ROSC). Fifty-four patients were included in the study. Protocol deviations occurred in one patient receiving tenecteplase and one patient receiving alteplase (4.0% vs 3.4%; P = 1.0). There was no difference in all-cause mortality (80% vs 86.2%; P = .72), any bleed (12% vs 13.8%; P = 1.0), major bleed (8.0% vs 6.9%; P = 1.0), or ROSC achievement (22.2% vs 28.6%; P = .73) when comparing tenecteplase to alteplase. Our study demonstrates that tenecteplase may be an alternative thrombolytic to alteplase for treatment of PE or cardiac arrest with suspected PE. Further studies comparing the different systemic thrombolytic agents for PE or cardiac arrest with suspected PE are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmbolismTenecteplaseTissue Plasminogen ActivatorFibrinolytic AgentsHeart ArrestHumansFemaleMaleMiddle AgedProspective StudiesAgedTreatment OutcomeThrombolytic TherapyHemorrhageAdult

Stichwörter der Autor:innen

PEalteplasecardiac arrestpulmonary embolismtenecteplase

Substanzen

TenecteplaseTissue Plasminogen ActivatorFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Pharmacy Services, Yale New Haven Hospital, New Haven, CT, USA.
  • Department of Pulmonary Critical Care, Yale School of Medicine, New Haven, CT, USA.

ORCID-Profile: Jessica M Daniell, Todd M Conner, Akhil Khosla

Zitieren

APA

Daniell, J. M., Mccormick, J., Nasreen, I., Conner, T. M., Rouse, G., Gritsenko, D., & Khosla, A. (2025). Comparison of Tenecteplase Versus Alteplase for the Treatment of Pulmonary Embolism and Cardiac Arrest with Suspected Pulmonary Embolism. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666241268539

Vancouver

Daniell JM, Mccormick J, Nasreen I, Conner TM, Rouse G, Gritsenko D, et al. Comparison of Tenecteplase Versus Alteplase for the Treatment of Pulmonary Embolism and Cardiac Arrest with Suspected Pulmonary Embolism. Journal of Intensive Care Medicine. 2025. doi:10.1177/08850666241268539

BibTeX
@article{Daniell2025,
  author = {Daniell, Jessica M and Mccormick, Jack and Nasreen, Iram and Conner, Todd M and Rouse, Ginger and Gritsenko, Diana and Khosla, Akhil},
  title = {Comparison of Tenecteplase Versus Alteplase for the Treatment of Pulmonary Embolism and Cardiac Arrest with Suspected Pulmonary Embolism},
  journal = {Journal of Intensive Care Medicine},
  year = {2025},
  doi = {10.1177/08850666241268539}
}
Kostenlos starten →